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Increasing evidence suggests that cancer stem cell (CSC) 
theory represents an important mechanism underlying the 
observed failure of existing therapeutic modalities to fully 
eradicate cancers. In addition to their more established role in 
maintaining minimal residual disease after treatment and 
forming the new bulk of the tumor, CSCs might also critically 
contribute to tumor recurrence and metastasis. For this reason, 
specific elimination of CSCs may thus represent one of the 
most important treatment strategies. Emerging evidence has 
shown that CSCs have a different metabolic phenotype to that 
of differentiated bulk tumor cells, and these specific metabolic 
activities directly participate in the process of CSC transfor-
mation or support the biological processes that enable tumor 
progression. Exploring the role of CSC metabolism and the 
mechanism of the metabolic plasticity of CSCs has become a 
major focus in current cancer research. The targeting of CSC 
metabolism may provide new effective therapies to reduce the 
risk of recurrence and metastasis. In this review, we 
summarize the most significant discoveries regarding the 
metabolism of CSCs and highlight recent approaches in 
targeting CSC metabolism. [BMB Reports 2018; 51(7): 319-326]
INTRODUCTION
Otto Warburg, a German biochemist who won the Nobel 
Prize in the 1930s, first discovered that tumor cells use a 
different metabolic pathway than normal cells. Since then, the 
field of cancer metabolism has become a new area of interest, 
especially in the last decade. Through the technical 
development of new biochemical tools such as metabolomics, 
studies of cancer cell metabolism have extended our 
knowledge of the mechanisms and role of metabolic 
reprogramming in cancer for tumor growth, metastasis, and 
drug resistance (1). Genomic instability and the diverse 
microenvironment condition contribute to the heterogeneity of 
tumors, and the existence of small subpopulations of cancer 
cells with high capacity for self-renewal and the ability to 
initiate tumorigenesis found in primary tumors, which are 
referred to as cancer stem cells (CSCs) (2, 3). CSCs are 
considered as the source from which cancer cells arise, and 
they are therapy resistant and responsible for metastatic 
dissemination, thereby CSC-targeted therapy would be an 
important challenge in cancer research (3). It is well-known 
that the metabolic reprogramming of pluripotent stem cells is 
essential for stem cell function (4, 5). Similar to normal stem 
cells, recent studies suggest that CSCs undergo metabolic 
changes including mitochondrial respiration and glycolysis, 
and this transition is critical for the function of CSCs (6). 
Therefore, targeting of the CSC metabolism may provide new 
therapies to reduce the risk of recurrence and metastasis (Fig. 
1). However, results regarding the metabolic phonotype of 
CSCs, which mainly utilize glycolytic or mitochondrial 
respiration, are contradictory, and the exact role of the precise 
metabolic reprogramming in cancer and underlying detailed 
mechanisms regulating this metabolic plasticity need to be 
elucidated. This review highlights the role of the metabolic 
reprogramming of CSCs and the differences in the metabolic 
pathway between CSCs and normal tissues. This review also 
explores the potential for the regulation of the metabolic 
pathway via new anti-cancer drugs.
TUMOR CELL METABOLISM
In non-transformed or quiescent somatic cells, mitochondria 
are the subcellular organelle that produce the principal source 
of energy through the tricarboxylic acid (TCA) cycle linked 
with oxidative phosphorylation (OXPHOS). Cells uptake 
carbon fuels such as glucose, fatty acids, and glutamine that 
enter into the TCA cycle to produce 36 ATPs with maximum 
efficiency in the mitochondria. Normal cells have a metabolic 
pathway designed to minimize the use of energy. However, 
highly proliferating cancer cells use glycolysis rather than 
OXPHOS for ATP generation, despite the presence of 
sufficient oxygen concentrations in the tumor micro-
environment (1, 7). Aerobic glycolysis in many cancers is 
caused by various factors, such as the hypoxic tumor 
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Fig. 1. Impact of CSCs on the effectiveness of anticancer therapy. CSCs are a small sub population of bulk tumor cells that are highly 
chemo-resistant and play a prominent role in tumor relapse. While conventional therapy results in a transient reduction in the tumor by 
killing non-stem cancer cells (differentiated cancer cells), the remaining CSCs can form recurring tumors, and metastasis is induced by the 
formation of a secondary colony in distant organs. The use of CSC-specific inhibitors would reduce therapy resistance and relapse, and 
prevent metastasis, with a loss of stem cell properties.
microenvironment, activation of oncogenes and loss of tumor 
suppressors, and mitochondrial DNA mutation. While cancer 
cell metabolism does not efficiently produce ATP, it allows 
cancer cells to rapidly divide and grow. Consequently, cancer 
cells produce a substantial portion of their energy from aerobic 
glycolysis which is more rapid than OXPHOS, although the 
aerobic glycolysis is considerably less efficient in terms of the 
amounts of ATP produced per unit of glucose consumed. This 
inefficient metabolic process is useful for producing the 
nucleic acids, amino acids, and lipids necessary for rapid cell 
growth via glycolysis and OXPHOS intermediates (8, 9). To 
compensate for this inefficient metabolic process for energy 
production per unit of glucose consumed, cancer cells uptake 
glucose and glutamate at a rate of more than about 200 times 
that of normal cells. In addition to glucose and glutamate as 
the core metabolic sources, increasing body of evidence 
suggests that various nutrients and metabolic pathways support 
the altered energy metabolism of cancer cells. Various 
metabolic fuel sources have been identified in cancer cells. 
These include acetate, lactate, fatty acids, serine, glycine, and 
branched chain amino acids. 
The metabolic alteration of cancer cells also has a beneficial 
effect on cancer survival and resisting cell death. The 
environmental conditions of cancer cells compared to those of 
normal cells is spatially and temporally heterogeneous and 
frequently sparse in levels of glucose, glutamine, and oxygen 
(10). The altered metabolic pathway of cancer cells enables 
cancer cells to survive in these metabolically stressful 
conditions found in the tumor microenvironment (such as low 
oxygen or nutrient levels) (11). It is known that the 
mitochondrial membrane permeabilization process, which is a 
mitochondrial apoptosis control mechanism, is inactivated in 
most cancer cells. These cytopathic mechanisms are known to 
be regulated by mitochondrial metabolism, especially 
hexokinase related with the glycolysis pathway; changes in 
cancer metabolism are therefore closely related to the 
anti-apoptotic property of cancer cells (12). In addition, 
changes in the metabolic pathway have been shown to be 
involved in gene expression by regulating the activity of 
epigenetic modification enzymes or by controlling the amount 
of substrate for epigenetic modification. Somatic mutations in 
IDH1 and IDH2 occur in up to 70% of glioma as well as in 
20% of leukemia, and these IDH mutants acquire a neomorphic 
activity to convert -ketoglutarate to (D)-2-hydroxyglutarate. 
The subsequent accumulation of 2-hydroxyglutarate results in 
epigenetic dysregulation via inhibition of -ketoglutarate- 
dependent histones and DNA demethylases, and suppress 
expression of many tumor suppressor gene (13-15). Lactate, a 
final product of glycolysis, acidifies the surrounding 
environment of cancer cells, inhibits the activation of NK and 
CTL cells, and plays an important role in the growth of cancer 
(16). Therefore, the reprogramed metabolic pathway of cancer 
plays an important role not only in tumor growth, but also in 
metastasis and chemo resistance through energy supply, 
survival under unfavorable environmental conditions, immune 
avoidance, and epigenetic modification (Fig. 2). 
CANCER STEM CELL
The heterogeneous nature of cell populations within a tumor 
has been recognized for several decades (3, 17). CSCs are 
defined as undifferentiated, slow-cycling cells that are able to 
form tumor tissue even from a single cell. In accordance with 
CSC model, heterogeneous and hierarchical cellular organiza-
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Fig. 2. Functions of metabolic alteration in cancer. Genetic mutations and growth signals in cancer cells and microenvironments within 
large tumors can dynamically alter metabolic pathways and modulate the regulation of metabolic pathways. This results in increased 
biosynthesis and abnormal bioenergy production, both of which promote cell proliferation, avoidance of immune-based destruction, 
metastasis, and survival. Furthermore, metabolic remodeling regulates tumor epigenetic alterations by regulating the activity of epigenetic 
modification enzymes because of the effect on gene expression in cancer.
tion have been found in most tumors, with a group of 
undifferentiated cells at the apex of the hierarchy. CSCs 
typically exist as minority subpopulation within the entire 
tumor mass (0.001-0.1%) and are responsible for the 
generation of highly proliferative cancer cells forming the bulk 
of the tumor, even in the recurrence of cancer after therapy 
(17-19). After prospective identification of CSCs in leukemia 
for the first time in 1994 (20), CSCs have been continuously 
identified in various solid tumors including those of breast 
cancer (21, 22), brain tumors (23, 24), colorectal cancer (25), 
prostate cancer (26), lung cancer (27), and melanoma (28). 
This new concept for intraclonal and functional heterogeneity 
of cancer cells can fundamentally change the way we 
diagnose and treat cancer. Accumulating evidence suggests 
that CSCs are responsible for metastasis, chemoresistance, and 
tumor relapse, and the elimination of CSCs may thus represent 
one of the most important challenges in treatment of cancer (3, 
29, 30).
CSCs possess various biological features of normal stem 
cells: the self-renewal ability; the expression of surface markers 
such as CD44, CD133, and aldehyde dehydrogenase; the 
activation of particular signaling pathways such as Wnt, 
Hedgehog, or Notch (17). Not only stem cells but also CSCs 
require a finely-tuned balance between self-renewal and 
differentiation. While the origin of CSCs is still unclear, CSCs 
are known to remain in the G0 phase, a quiescent phase, and 
express a high drug efflux transport system. CSCs, especially 
since they are in a dormant state, are almost impossible to 
eliminate by general anti-cancer drugs, which usually target 
proliferating cancer cells, and targeted therapies for CSCs are 
therefore needed (33, 34). An important feature of embryonic 
stem cells is their special metabolic phenotype when 
compared with differentiated progenies (35). Similar to cancer, 
it is well-known that metabolic alterations regulate stem cell 
self-renewal, and stem cell function is also regulated by 
bioenergetic signaling, such as the AKT-mTOR pathway, 
glutamine metabolism, and fatty acid metabolism (31). 
Emerging evidence strongly suggests that CSCs also undergo 
metabolic alterations (including mitochondrial respiration, 
glycolytic activity, and altered lipid metabolism) that are 
critical for CSC function. Furthermore, low oxygen tension 
(hypoxia) contributes to the maintenance of an undifferen-
tiated state and influences proliferation and cell-fate commitment 
in normal stem cells. It is also well-known that hypoxia is a 
critical factor for malignancy, chemoresistance, and poor 
survival rate of cancer patients (32). Thus, exploiting the 
metabolism changes required for CSC self-renewal, cell 
division, and quiescence may provide effective therapies and 
diminish the risk of recurrence and metastasis.
METABOLIC STATE OF CANCER STEM CELLS 
It has been well verified that pluripotent stem cells mainly 
utilize glycolysis for energy production, whereas normal cells 
rely on OXPHOS (4). In induced pluripotent stem cells (iPS 
cells) as a model of stem cell reprogramming, glycolytic 
metabolic changes occur from OXPHOS prior to their 
acquisition of the pluripotent state, and this process is essential 
for stem cell reprogramming (36). These findings suggest that 
metabolic reprogramming and stemness are closely linked, 
and the glycolytic switch could play a critical role in CSCs 
rather than the consequence of acquiring pluripotency. Many 
studies have been supported the hypothesis that CSCs are 
more glycolytic than normal cancer cells. Similar to normal 
stem cells, glucose is an essential nutrient for CSCs, and its 
presence in the microenvironment significantly increases the 
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Fig. 3. Metabolic features of CSCs. In non-stem/highly proliferative cancer cells, glycolysis is a predominant metabolic phenotype 
contributing to tumor growth. CSCs rely on OXPHOS metabolism or combined metabolism with high glycolysis, depending on the 
oncogenic background and surrounding microenvironment conditions such as hypoxia or nutrient supplementation. CSCs also show 
metabolic plasticity between two metabolic phenotypes. However, in either case, mitochondrial function is critical for CSC functions such 
as stemness, migration, and drug resistance.
number of stem-like cancer cells in the cancer cell population. 
Glucose induces the expression of specific genes in CSCs 
associated with the glucose metabolism pathway (c-Myc, 
Glut-1, HK-1, HK-2, and PDK-1), which contributes to the 
increase in the CSC population (37). Furthermore, glycolysis 
inhibition or deprivation of glucose leads to a decline in the 
CSC population. Small cell populations with stem-like properties 
from glioblastoma, ovarian cancer, breast cancer, lung cancer, 
and colon cancer cell lines rely more on glycolysis than on the 
bulk of differentiated progeny (38-41). As a typical glycolytic 
cell, glucose uptake, lactate production, glycolytic enzyme 
expression, and ATP content are significantly increased in 
CSCs compared to non-CSCs. The stemness marker CD44 is 
crucial for the regulation of glycolytic metabolism (42). 
Additionally, CSCs of glioblastoma that are highly dependent 
on glycolysis show increased migration in hypoxic conditions. 
Glycolysis was found to be the preferred metabolic state in 
radiotherapy-resistant stem cells in nasopharyngeal carcinoma 
and hepatocellular carcinoma. Therefore, glycolytic metabolic 
reprogramming is critical for the maintenance of CSCs and is 
associated with the progression of cancer.
While the above reported studies show that CSCs mainly 
rely on glycolysis, several other studies showed that CSCs 
possess a preference for mitochondrial oxidative metabolism. 
Growing evidence has demonstrated that quiescent or 
slow-cycling tumor-initiating CSCs are less glycolytic, consume 
less glucose, and produce less lactate, whereas they contain 
higher ATP levels than their differentiated cancer progeny cells 
in many other tumor types including lung cancer, breast 
cancer, glioblastoma, and pancreatic cancer (43-46). Moreover, 
it has been reposted that CSCs have an increased 
mitochondrial mass and membrane potential with enhanced 
oxygen consumption rates. Additionally, invasive cancer cells 
show high mitochondrial metabolism through the expression 
of transcription factor PGC1, the master regulator of 
mitochondrial biogenesis (47, 48). PGC1 has also been 
found to be overexpressed in circulating tumor cells, and the 
inhibition of PGC1 reduces the stemness properties of breast 
CSCs (49). In addition, NANOG, a pluripotency gene, induces 
tumorigenesis through metabolic reprogramming to OXPHOS 
and fatty acid metabolism (50). The increased OXPHOS 
phenotype and expression of PGC1 seems to be related to 
the capacity for chemoresistance in CSCs (51-54). Surviving 
cells from chemotherapy rely on oxidative phosphorylation 
through increased mitochondrial activity. It has been reported 
that MYC and MCL1 cooperatively promote chemotherapy- 
resistant breast CSC via the regulation of mitochondrial 
OXPHOS (54). A recent study showed that the mitochondrial 
DNA transfer from host cells to tumor cells re-establishes the 
tumor-initiating and drug resistance capacity of the tumor calls 
(55). In contrast to normal stem cells and iPS cells, which 
mainly utilize glycolysis, CSCs show a distinct metabolic 
phenotype that can be glycolytic or OXPHOS-dependent. 
However, growing evidence strongly suggests that in either 
case, mitochondrial function is critical and plays a crucial role 
in CSC functions such as stemness, migration, and drug 
resistance (Fig. 3). 
Metabolic complexity of cancer stem cells
Young Chan Chae and Jae Ho Kim
323http://bmbreports.org BMB Reports
GLUTAMINE AND LIPID METABOLISM IN CSCs
It has become increasingly clear that the unique model of 
cancer metabolic reprogramming can neither be universally 
applied to the entire spectrum of cancer types, nor to the 
various intrinsic subtypes of cancer cells in tumors. Glycolysis 
and OXPHOS alone cannot accurately account for cancer 
stem cell metabolism because the metabolic pathway is 
intricately intertwined. In addition to glucose metabolism, 
CSCs also rely on glutamine, which provides the carbon and 
amino-nitrogen needed for biosynthesis of amino-acid, 
nucleotide, and lipids (56). Therefore, glutamine metabolism is 
intertwined with glucose metabolism and can complement 
each other. In some cancers, glutamine helps to compensate 
for glucose shortages (57, 58). Moreover, emerging evidence 
suggests that alterations in lipid- and cholesterol-associated 
pathways are also essential for the maintenance of CSCs (59). 
In cancer cells, various metabolic intermediates are generated 
that can be utilized in anabolic processes for membrane 
building blocks. It is known that the lipid metabolic pathway is 
flexible and closely linked to the glucose and amino acid 
metabolic pathways in order to meet the increasing 
bioenergetics requirements of CSCs. The altered lipid 
metabolism may also affect the cytosolic oncogenic signaling 
pathway. Lipid rafts, which are rich in sphingolipids and 
cholesterol, are unique small lipid domains within the cell 
membrane in cancer cells and contain a set of receptors and 
signaling proteins involved in cell survival, adhesion, 
metastasis, and tumor progression (60-62). Lipid metabolic 
alteration in cancer can have an effect on cytosolic signaling 
changes via regulating lipid raft dynamics and components in 
CSCs. High lipid droplets and stored-cholesteryl ester content 
have been observed in circulating tumor cells, colorectal 
CSCs, and breast CSCs (63, 64). Actually, lipid droplets 
content and CD133 expression are directly correlated, and 
cancer cells with high lipid droplets have greater clonogenic 
potential and in vivo tumor-forming ability (63). Ovarian CSCs 
have high levels of unsaturated lipids, and blocking lipid 
desaturation impairs cancer stemness and tumor initiation 
capacity (65). It has been demonstrated that fatty acid 
oxidation pathways are critical for both hematopoietic stem 
cells, leukemia-initiating cells, and breast cancer stem cell 
functions (66, 67). The inhibition of fatty acid -oxidation 
preferentially eliminates CSC population. Furthermore, altered 
lipid metabolism has been shown to influence the 
aggressiveness and progression of cancer. Lipid droplet-rich 
colon cancer cells are more resistant to chemotherapy. It has 
also been found that fatty acid -oxidation is critical for 
self-renewal and chemoresistance of breast CSCs (66). In 
addition, lipid metabolism is closely associated with tumor 
metastasis (68).
METABOLIC COMPLEXITY OF CANCER STEM CELLS
CSCs may have highly glycolytic or OXPHOS phenotypes, 
depending on the cancer type. However, contradictory results 
regarding the metabolic phenotype in the same type of cancer 
have been reported. One possible reason for this type of 
contradictory result is the high flexibility of the metabolic 
phenotype of the CSCs between OXPHOS and glycolytic 
phenotypes depending on the environment and cellular 
signaling pathway. In support of this metabolically flexible 
scenario, it has been reported that CSCs are able to switch to a 
glycolytic metabolism when OXPHOS is blocked (69, 70). 
And most recently, it has been shown that MYC/PGC-1 
balance determines the metabolic phenotype and plasticity of 
pancreatic CSCs (45). It is well-known that the microen-
vironment around CSCs plays an important role in maintaining 
stemness. Different types of cancer in diverse tissues exist in 
considerably different microenvironments (different oxygen 
tension and glucose concentrations), so each CSC can show a 
different metabolic phonotype to adapt to the different 
environment condition. In glucose-rich environments, prolife-
rating CSCs primarily utilize aerobic glycolysis for their energy 
production, while in glucose-deprived conditions, CSCs shift 
to a quiescent and slow cycling state while relying on 
mitochondrial oxidative metabolism for ATP generation. 
Moreover, it has been shown that CSCs can adapt to hypoxia 
by upregulating the glucose metabolic enzymes and switching 
to a more glycolytic phenotype (70). Another factor that causes 
CSCs to have various metabolic phenotypes is the different 
signaling contexts and oncogenic mutations within cancer 
cells. The glycolytic metabolism phenotype and stemness of 
normal stem cells and iPS cells is mediated by OCT4, KLF4, 
SOX2, and MYC; however, NOTCH, WNT/-catenin, PI3K/Akt, 
PTEN, NF-kB, KRAS, HIF, TP53, and many oncogenic 
pathways are involved in retaining the stemness of CSCs. This 
can affect the metabolic phenotype of CSCs. Moreover, a 
subpopulation of CSCs (heterogeneity) exists in tumors, and 
these can exhibit different metabolic patterns with different 
genetic alterations. In summary, CSCs are able to dynamically 
transition between different metabolic states, and the role of 
diverse genetic backgrounds and microenvironments in the 
metabolic state of CSCs and tumorigenic potential still needs 
to be elucidated.
TARGETING CELLULAR METABOLISM
The metabolic targeting of CSCs has become a very important 
emerging area to address effective cancer therapy for the 
elimination of CSCs, which are responsible for chemo-resistance 
and tumor relapse. To inhibit glycolysis metabolism, glucose 
transporter and glycolytic enzymes such as GLUT1-4, 
Hexokinase1-2, Pyruvate kinase M2, and lactate dehydro-
genase have been suggested as targets (71). Another potential 
target is an adaptive mechanism of CSCs within the tumor 
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microenvironment. CSCs rapidly transit their metabolism 
under heterogeneous environmental conditions (such as 
hypoxia, glucose deprivation, and low pH); this adaptive 
metabolic response by CSCs plays a pivotal role in cancer 
metastasis or chemo-resistance. Hypoxic inducible factor 
HIF1-2 is a key enzyme for metabolic adaptation in hypoxia 
and is involved in angiogenesis, metastasis, and cell survival 
(72). Pyruvate dehydrogenase kinase 1 has been demonstrated 
to regulate the metabolic transition in hypoxia via regulating 
the amount of acetyl-coA, which is then oxidized in the 
mitochondria to produce energy in the TCA cycle (73). 
Furthermore, pyruvate dehydrogenase kinase 1 is enriched in 
breast CSCs and is critical for metastasis in hypoxia (74, 75). 
mTOR controls energy homeostasis and involves cell survival 
during cellular metabolic stress such as nutrient and energy 
depletion. The downregulation of mTOR signaling reduces 
CSC properties in pancreatic, breast, and colorectal cancer 
(76). CSCs dependent on OXPHOS can be targeted by 
impairing mitochondrial energy metabolism. It has been 
shown that Metformin and Phenformin inhibit the electron 
transport chain complex I and cause cell death by energy crisis 
in CSCs (45, 77). Inhibition of mitochondrial protein biosynthesis 
can block mitochondrial OXPHOS by the inhibition of 
mitochondrial ribosomes using Tetracyclines, which has 
toxicity against CSCs (78). Similarly, mitochondrial meta-
bolism can also be targeted by the mitochondrial chaperone 
TRAP1 inhibitor, Gamitrinib, which induces the impairment of 
protein folding in mitochondria (79, 80). Growing evidence 
strongly suggests that targeting mitochondrial OXPHOS could 
be an effective strategy to target CSCs and to reduce cancer 
metastasis and chemo-resistance. However, it is necessary to 
identify specific targets to inhibit OXPHOS only in CSCs and 
for the metabolic transition of CSCs without affecting normal 
cells that generally use OXPHOS to produce energy.
CONCLUSION
In various cancers, CSCs have been shown to have a distinct 
metabolic phenotype and can change their metabolic pathway 
depending on their microenvironment condition and genetic 
background. This complexity leads to more intricate variability 
in the metabolic pathways of CSCs. However, despite the 
limited research on the mechanism of metabolic plasticity of 
CSCs, recent studies strongly suggest that metabolic repro-
gramming in CSCs is crucial for tumorigenesis, metastasis, 
drug resistance, and tumor relapse. The targeting of the CSC 
metabolism is suggested as a novel therapeutic approach to 
eradicate the progression of various cancers. Since traditional 
anti-cancer drugs are inefficient in eliminating cancer and 
preventing its recurrence, targeting the metabolism of CSCs 
could provide a direction for the development of new 
anti-cancer drugs. A combination treatment with CSC-targeting 
drugs and conventional anticancer drugs could be a more 
effective strategy to treat cancer. Finally, to develop drugs that 
target the metabolic pathway of CSCs, the exact role of precise 
metabolic plasticity in cancer and the underlying detailed 
mechanism of regulating this metabolic plasticity should be 
elucidated. In addition, because of their metabolic similarity, 
an accurate distinction between CSCs and normal stem cells 
should be addressed. Once a specific metabolic pathway of 
CSCs has been identified, new therapies can be developed to 
eliminate CSCs without damaging normal cells.
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